Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors
L01EM03 Alpelisib
D11011 Alpelisib (JAN/USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Phosphatidylinositol-3-Kinase (PI3K) Inhibitors
Alpelisib
D11011 Alpelisib (JAN/USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG03139 PI3K inhibitor
D11011 Alpelisib
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Phosphotransferase
PIK3CA* [HSA_VAR:5290v1]
D11011 Alpelisib (JAN/USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11011
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11011
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11011
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D11011